Video

Microvascular Disease Burden in Type 2 Diabetes

Does microvascular disease burden predict future cardiovascular events in type 2 diabetes? Dr. Bobby Lazzara discusses this question.

In this Medical News Minute, developed exclusively for Endocrinology Network, Dr. Bobby Lazzara reviews a cohort study examining the effect of microvascular disease burden on future cardiovascular events in type 2 diabetes. Researchers looked at the cumulative burden of retinopathy, nephropathy, and peripheral neuropathy in over 49,000 patients with type 2 diabetes.

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Related Content
Serum Uric Acid Levels Linked to Risk of Dyslipidemia in Type 2 Diabetes | Image Credit: National Cancer Institute
January 7th 2025

Serum Uric Acid Levels Linked to Risk of Dyslipidemia in Type 2 Diabetes

Connor Iapoce
Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas | Image Credit: HCPLive
January 6th 2025

Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
GLP-1 RA Discontinuations Frequent in People with Obesity Without Diabetes| Image Credit: Kenny Eliason/Unsplash
January 3rd 2025

GLP-1 RA Discontinuations Frequent in People with Obesity Without Diabetes

Connor Iapoce
Diabetes Dialogue: Insights on INHALE-1 and CATALYST Trials | Image Credit: HCPLive
January 2nd 2025

Diabetes Dialogue: Insights on INHALE-1 and CATALYST Trials

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Logo | Credit: US Food and Drug Administration
December 23rd 2024

FDA Approves Generic Once-Daily GLP-1 RA for Type 2 Diabetes in Pediatric, Adult Patients

Patrick Campbell
David Tak Wai Lui I Credit: ResearchGate
December 20th 2024

Study Shows a U-Shaped Association Between HDL-C, Major Adverse Cardiovascular Events

Chelsie Derman
© 2025 MJH Life Sciences

All rights reserved.